Common Questions in the treatment of VTE: Dr Mari Thomas
Dr Mari Thomas provides evidence-based answers to common questions in the treatment of VTE with Xarelto (rivaroxaban) in a series of short videos:
Footnotes
Xarelto 10 mg, 15 mg and 20 mg, along with the 15 mg and 20 mg treatment initiation packs, are all indicated for the treatment of DVT and PE, and prevention of recurrent DVT and PE in adults.
Please see the Xarelto® summaries of product characteristics for more information and to view other indications. Patients with malignant disease may simultaneously be at higher risk of bleeding and thrombosis.
The individual benefit of antithrombotic treatment should be weighed against risk for bleeding in patients with active cancer. Tumours located in the gastrointestinal or genitourinary tract have been associated with an increased risk of bleeding during rivaroxaban therapy.
In patients with malignant neoplasms at high risk of bleeding, the use of rivaroxaban is contraindicated.
BD: twice daily; DOAC: direct oral anticoagulant; DVT: deep vein thrombosis; GI: gastrointestinal; PE: pulmonary embolism
RP-XAR-GB-5302 | February 2024